SG11202103284QA - Formulations containing deuterated domperidone - Google Patents
Formulations containing deuterated domperidoneInfo
- Publication number
- SG11202103284QA SG11202103284QA SG11202103284QA SG11202103284QA SG11202103284QA SG 11202103284Q A SG11202103284Q A SG 11202103284QA SG 11202103284Q A SG11202103284Q A SG 11202103284QA SG 11202103284Q A SG11202103284Q A SG 11202103284QA SG 11202103284Q A SG11202103284Q A SG 11202103284QA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations containing
- deuterated domperidone
- containing deuterated
- domperidone
- formulations
- Prior art date
Links
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical class C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862750491P | 2018-10-25 | 2018-10-25 | |
| PCT/US2019/058033 WO2020086947A1 (en) | 2018-10-25 | 2019-10-25 | Formulations containing deuterated domperidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103284QA true SG11202103284QA (en) | 2021-05-28 |
Family
ID=68582416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103284QA SG11202103284QA (en) | 2018-10-25 | 2019-10-25 | Formulations containing deuterated domperidone |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220110929A1 (es) |
| EP (1) | EP3668510B1 (es) |
| JP (2) | JP2022512041A (es) |
| KR (3) | KR20240068762A (es) |
| CN (1) | CN113164463B (es) |
| AU (1) | AU2019366993B2 (es) |
| CA (1) | CA3117682A1 (es) |
| ES (1) | ES2852623T3 (es) |
| IL (1) | IL282575B (es) |
| SG (1) | SG11202103284QA (es) |
| WO (1) | WO2020086947A1 (es) |
| ZA (1) | ZA202102115B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023205368A1 (en) * | 2022-04-20 | 2023-10-26 | Cindome Pharma, Inc. | Deuterated domperidone for treating gastroparesis |
| WO2024197230A1 (en) * | 2023-03-23 | 2024-09-26 | Cindome Pharma, Inc. | Methods for treating diabetic gastroparesis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050220825A1 (en) * | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
| CN1686128A (zh) * | 2005-04-19 | 2005-10-26 | 北京正大绿洲医药科技有限公司 | 多潘立酮滴丸及其制备方法 |
| WO2008134540A1 (en) * | 2007-04-26 | 2008-11-06 | Aronchick Craig A | Compositions and methods for transmucosal delivery of domperidone |
| DE102010015143A1 (de) * | 2010-04-16 | 2011-10-20 | Cts Chemical Industries Ltd. | Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| CN113995755A (zh) * | 2016-02-04 | 2022-02-01 | 辛多美制药有限公司 | 氘代多潘立酮组合物和用于治疗病症的方法 |
-
2019
- 2019-10-25 CA CA3117682A patent/CA3117682A1/en active Pending
- 2019-10-25 CN CN201980069226.8A patent/CN113164463B/zh active Active
- 2019-10-25 ES ES19804996T patent/ES2852623T3/es active Active
- 2019-10-25 WO PCT/US2019/058033 patent/WO2020086947A1/en unknown
- 2019-10-25 KR KR1020247014648A patent/KR20240068762A/ko active Search and Examination
- 2019-10-25 JP JP2021547550A patent/JP2022512041A/ja active Pending
- 2019-10-25 EP EP19804996.7A patent/EP3668510B1/en active Active
- 2019-10-25 KR KR1020217015511A patent/KR20210080495A/ko not_active IP Right Cessation
- 2019-10-25 US US17/287,571 patent/US20220110929A1/en active Pending
- 2019-10-25 AU AU2019366993A patent/AU2019366993B2/en active Active
- 2019-10-25 KR KR1020237041657A patent/KR102667995B1/ko active IP Right Grant
- 2019-10-25 SG SG11202103284QA patent/SG11202103284QA/en unknown
-
2021
- 2021-03-29 ZA ZA2021/02115A patent/ZA202102115B/en unknown
- 2021-04-22 IL IL282575A patent/IL282575B/en unknown
-
2022
- 2022-12-09 JP JP2022196699A patent/JP2023036663A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL282575A (en) | 2021-06-30 |
| KR20230169456A (ko) | 2023-12-15 |
| BR112021007754A2 (pt) | 2021-07-27 |
| EP3668510A1 (en) | 2020-06-24 |
| EP3668510B1 (en) | 2021-01-13 |
| JP2023036663A (ja) | 2023-03-14 |
| IL282575B (en) | 2022-05-01 |
| CA3117682A1 (en) | 2020-04-30 |
| WO2020086947A1 (en) | 2020-04-30 |
| KR102667995B1 (ko) | 2024-05-23 |
| CN113164463A (zh) | 2021-07-23 |
| KR20240068762A (ko) | 2024-05-17 |
| AU2019366993B2 (en) | 2024-02-15 |
| ES2852623T3 (es) | 2021-09-14 |
| CN113164463B (zh) | 2022-09-20 |
| KR20210080495A (ko) | 2021-06-30 |
| JP2022512041A (ja) | 2022-02-01 |
| AU2019366993A1 (en) | 2021-05-06 |
| US20220110929A1 (en) | 2022-04-14 |
| ZA202102115B (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201809976D0 (en) | Novel formulations | |
| IL287224A (en) | New formulations containing melphalan | |
| GB201707189D0 (en) | Novel formulations | |
| GB201707188D0 (en) | Novel formulations | |
| IL283450A (en) | capsule formulations | |
| IL282575B (en) | Formulations that include deuterated domperidone | |
| GB201904338D0 (en) | Fluorouracil-containing formulations | |
| PT4045038T (pt) | Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida | |
| IL290356A (en) | Formulations for Resotide | |
| GB201707187D0 (en) | Novel formulations | |
| IL284691A (en) | formulations | |
| SG11202012165WA (en) | Formulations/compositions comprising ibrutinib | |
| SG11202010097WA (en) | Apixaban formulations | |
| PT3651736T (pt) | Formulações de longa ação | |
| IL282576B (en) | Preparations that include domperidone | |
| GB201911063D0 (en) | Formulations | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201905105D0 (en) | Formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| GB201905878D0 (en) | Retentive formulation | |
| GB201910092D0 (en) | New formulations | |
| GB201910093D0 (en) | New formulations | |
| GB201808386D0 (en) | Formulations | |
| GB201804545D0 (en) | Formulations | |
| GB201803201D0 (en) | Formulations |